NRx Pharmaceuticals (NASDAQ:NRXP) and Jaguar Animal Health (NASDAQ:JAGX) Head to Head Comparison

NRx Pharmaceuticals (NASDAQ:NRXP) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Institutional and Insider Ownership

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Jaguar Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares NRx Pharmaceuticals and Jaguar Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Jaguar Animal Health	-187.88%	N/A	-131.45%

Earnings & Valuation

This table compares NRx Pharmaceuticals and Jaguar Animal Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23 million	105.08	-$28.62 million	($0.55)	-5.43
Jaguar Animal Health	$11.51 million	0.15	-$53.43 million	($3,731.33)	-0.00

NRx Pharmaceuticals has higher earnings, but lower revenue than Jaguar Animal Health. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for NRx Pharmaceuticals and Jaguar Animal Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2	0	5	0	2.43
Jaguar Animal Health	1	0	0	0	1.00

NRx Pharmaceuticals presently has a consensus price target of $34.50, indicating a potential upside of 1,055.78%. Given NRx Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Jaguar Animal Health.

Volatility and Risk

NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Summary

NRx Pharmaceuticals beats Jaguar Animal Health on 9 of the 13 factors compared between the two stocks.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.